In tableting operations for pigs and calves, Xiaoshu Anshen Powder Veterinary Grade API is pre-blended with microcrystalline cellulose at a ratio of 1:3 wt/wt before entering a high-shear granulator; this pre-blend compensates for the fibrous herbal fraction that otherwise increases die-wall friction and causes sticking on 10-station rotary press tooling. The working formula for a 500 mg target tablet is API 8.0 wt%, microcrystalline cellulose 46.0 wt%, lactose monohydrate 38.0 wt%, crospovidone 6.0 wt%, magnesium stearate 0.8 wt%, and talc 0.2 wt%; purified water is added at 23.0–27.0 wt% of the dry blend. Wet massing is performed in a top-drive high-shear granulator at impeller 220 rpm, chopper 1400 rpm, and massing time 3.5 min. The wet mass is passed through an oscillating sieve fitted with a 1.2 mm screen, then dried in a fluid-bed dryer at inlet air 55–65°C until loss on drying is < 4.0%. Tablets are compressed at 12–18 kN, with ejection force maintained below 2500 N. Hardness is held at 50–70 N, friability is < 1.0% by USP <1216>, and disintegration is < 15 min in 0.1 M hydrochloric acid at 37±2°C by USP <701>. Terminal product is a 500 mg film-coated tablet containing 40 mg API per unit.

Release testing for the tablet requires HPLC-UV quantitation of the dried-powder marker profile against a qualified reference standard; content uniformity acceptance value is ≤ 15 by USP <905>. If the API moisture content exceeds 6.0% at incoming inspection, pre-drying at 50°C for 2 h is required before granulation. Batch records from production-scale campaigns indicate that granule flow, rather than API potency, is the main source of weight variation; over-lubrication above 1.0 wt% magnesium stearate delays disintegration beyond specification. The tablet formulation is not directly transferable to mini-tablets below 3 mm diameter without re-optimizing the microcrystalline cellulose ratio because die fill becomes erratic when the API particle fraction exceeds 30% by sieve analysis. Component testing under 21 CFR 211.84 and process validation under 21 CFR 211.110 apply for export batches destined for FDA-regulated jurisdictions.

Why Sterile Filtration of Xiaoshu Anshen Powder Requires a Two-Stage Decarbonization and pH Back-Titration Before 0.22 µm Membrane Passage

Injectable solutions derived from powdered herbal API present a distinct filtration bottleneck. The dried extract contains water-soluble polysaccharides, pectin-like colloids, and residual fine herb leaf fragments that pass through an 80-mesh pre-sieve but foul a 0.22 µm membrane within the first 2 L of flow per square meter. A two-stage clarification is therefore placed before final sterilizing filtration: the reconstituted bulk solution is mixed with pharmaceutical activated carbon at 0.1% w/v, stirred at 50°C for 15 min, then passed through a 0.45 µm PVDF filter. The filtrate is back-titrated with 1.0 M sodium hydroxide or 0.5 M citric acid to pH 5.5–6.5. The working concentration is 10.0 mg/mL dry extract equivalent; a 12.5 g API charge per 1000 mL Water for Injection compensates for carbon adsorption and membrane hold-up losses of approximately 20%.

After pre-filtration, the bulk is cooled to 20–25°C and filtered through a 0.22 µm PVDF sterilizing cartridge at a differential pressure of 0.8–1.2 bar. Post-filtration bubble point is not less than 3.0 bar. Sterility is verified by USP <71>, bacterial endotoxin limit is 0.5 EU/mg by USP <85>, and particulate matter is controlled according to USP <788> for small-volume injections. Because terminal autoclaving at 121°C for 15 min produces measurable peak-area loss of heat-labile flavonoid glycosides and increases browning, aseptic filling under ISO 14644-1:2015 ISO Class 5 is specified. Terminal product is a 10 mL amber glass ampoule or a 50 mL multi-dose vial with 0.2% w/v benzyl alcohol; multi-dose containers must not be used beyond 28 days after first broaching unless a preservative effectiveness study supports a longer in-use period. Published data for this specific configuration is limited, so each production campaign must include a forced-degradation bracketing study for the reconstituted bulk.

Operational boundaries for injectable processing are narrow. If pH falls below 5.0, precipitation of the aglycone fraction appears as visible haze; if pH exceeds 6.8, alkaline hydrolysis of ester-linked phenolic acids accelerates and produces chromatographic impurity drift above the acceptance limit of 2.0% total impurities. The API must not be exposed to polyvalent metal ions; 316L stainless steel contact surfaces are acceptable only after passivation, because free iron ions catalyse oxidative colour change in the reconstituted liquid. Dissolved oxygen is reduced below 0.5 mg/L by nitrogen sparging before filling; amber glass protects against light-induced degradation. Stability under 25°C/60% RH for 12 months is monitored by a bracketed protocol according to VICH GL3. Avoid combination with amine-based tonicity adjusters unless compatibility data demonstrate no adduct formation with the caffeoylquinic acid fraction.

Low-Dust Capsule Fill and Moisture-Driven Potency Loss in Hard Gelatin Encapsulation

Direct-encapsulation of Xiaoshu Anshen Powder Veterinary Grade API is assigned to hard gelatin capsules only after the powder has been milled through an 80-mesh stainless steel sieve and pre-blended with fumed silica at 1.0 wt% to reduce hygroscopic tack. The direct-encapsulation formula for a size 1 hard gelatin capsule at 300 mg fill weight is API 20.0 wt%, lactose monohydrate 74.0 wt%, sodium starch glycolate 5.0 wt%, and fumed silica 1.0 wt%. The blend is processed at relative humidity < 45% and 20–25°C; if the API moisture content exceeds 6.0%, pre-drying at 50°C for 2 h is required. Encapsulation is performed on a tamping-pin capsule filler operating at 60,000 capsules/h, with dust extraction velocity 0.5 m/s at the filling station. Weight variation is controlled with a limit of ± 5.0% for individual capsules, content uniformity acceptance value is ≤ 15 by USP <905>, and disintegration is < 10 min in water at 37±2°C by USP <701>. Terminal product is a 300 mg hard gelatin capsule providing 60 mg API per capsule.

Moisture-driven tack remains the primary failure mode; production-scale records from high-RH campaigns show elevated coefficient of variation when relative humidity exceeds 55% for more than 4 h. The process is not suitable for enteric-coated capsules because the powdered API does not support pH 1.2–5.5 differential release testing without a protective pellet core. For export batches, component acceptance testing under 21 CFR 211.84 and in-process sampling under 21 CFR 211.110 apply. If capsule filling is performed in a shared facility, cleaning validation for herbal marker carryover must meet a residual limit of 10 ppm in the next product, calculated on a matrix-specific basis.

When Medicated Feed Incorporation at 2.5 kg Per Metric Tonne Demands Carrier Particle Size Control to Maintain Homogeneity

A direct metered inclusion of the raw API into a finished feed line produces unacceptable assay variability because the active particle count is too low for homogeneous distribution and because the fine powder generates dust containing respirable herbal particles. A stepwise dilution is therefore used: an intermediate premix is prepared at 10.0 wt% API in ground corn cob carrier sized 595–841 µm, then diluted 1:10 with solvent-extracted soybean meal to a final premix containing 1.0 wt% API. The intermediate premix is mixed in a horizontal ribbon mixer at 40 rpm for 12 min; the final feed is mixed in a twin-shaft paddle mixer at 25 rpm for 8 min. Homogeneity is verified by taking 10 samples at discharge according to ISO 6497:2002 and analysing a marker constituent by HPLC; the target coefficient of variation is ≤ 5.0%. Terminal product is a 25 kg paper bag of medicated premix or bulk feed containing 250 g API per metric tonne when added at the specified inclusion rate.

Carryover limits are established under Regulation (EU) 2019/4, with a post-production flush of 50 kg ground corn carrier between batches. In the United States, medicated feed production falls under 21 CFR Part 507 preventive controls; sampling plans must be documented. Operational boundaries include avoiding molasses-based carriers: residual molasses films above 2.0% w/w cause API particles to stick to mixer walls and create hot spots with assay deviation above 15%. Carrier particle size is critical; if more than 30% of carrier passes through a 250 µm sieve, dust concentration exceeds 5 mg/m³ at the bagging station and the premix segregates during discharge from hopper-bottom bins. The API must not be mixed at high shear with expanded perlite or crystalline silica carriers, because attrition generates glassy fines that abrade the ribbon mixer shaft seal and increase the risk of foreign particulate contamination in the finished feed.

Dissolution Profile Shifts when API Powder Is Introduced Directly into Acidified Drinking Water Without a Water-Soluble Carrier

Drinking-water administration of this API powder is blocked by sedimentation and nozzle fouling unless a water-soluble granule intermediate is generated first. The water-soluble granule formula is API 20.0 wt%, maltodextrin 53.0 wt%, povidone K30 5.0 wt%, anhydrous sodium sulfate 20.0 wt%, and colloidal silicon dioxide 2.0 wt%. The mixture is wet-granulated with purified water in a high-shear mixer, dried to moisture < 3.5%, and sieved to 850–2000 µm. The granule must disperse to 95% within 2 min in water at 25°C under gentle stirring; residue above 5.0% after 2 min indicates over-drying of the maltodextrin bridge. The final in-feed water concentration is 0.5 g API per litre, prepared by adding 2.5 g of the water-soluble granule per litre. The solution is used within 24 h.

Water hardness above 250 mg/L CaCO₃ produces visible haze from complexation of organic acids; EDTA tetrasodium can be added at 0.1% w/v as a chelating agent but must not exceed 0.2% w/v because higher EDTA concentrations impart a bitter taste that suppresses drinking in pigs. pH is held at 4.5–5.5; acidification below 4.0 with citric acid accelerates dissolution but destabilizes polysaccharide fractions and increases precipitate after 6 h. Terminal product is a 100 g water-soluble sachet delivering 20 g API per sachet. Release testing includes loss on drying by USP <731>, HPLC assay, and a dispersibility check under a validated in-house method based on CIPAC MT 179 for water-dispersible granules. For drinking water systems with header tank volume above 1000 L, a stock solution at 20.0 wt% is impractical; the granular formulation should be predispersed in a separate make-up tank before introduction into the main line.

Fluid-bed agglomeration is used when individual dosing accuracy becomes more important than bulk feed mixing; sow and calf recovery pens often show feed intake deviations above 20%, so top-dress granules permit direct oral administration without relying on group consumption. Xiaoshu Anshen Powder API is agglomerated in a Glatt GPCG 3.1 fluid-bed system with a binary binder solution of povidone K30 5.0 wt% and maltodextrin 2.0 wt%; the API content is 25.0 wt% in the final granule. Dry powder feed rate is 1.5 kg/h, inlet air temperature 60±2°C, atomizing air pressure 1.2 bar, and air flow is adjusted to maintain a product bed temperature of 38–42°C. The final granule is classified through 850 µm and 2000 µm sieves; undersized fines are recycled, and oversized granules are milled through a 1.0 mm screen. Moisture is held at < 3.5% by Karl Fischer titration per USP <921> Method Ia. The terminal product is a 10 g aluminium foil sachet containing 2.5 g API per sachet; one 1.0 g granule dose provides 250 mg API. Content uniformity acceptance value is ≤ 15 by USP <905>.

Stability of the granule under accelerated conditions at 40°C/75% RH for 6 months is bracketed by VICH GL3; batch-to-batch variance in bulk density must not exceed ± 5.0% because flow through volumetric dosing spoons changes with density. The granulation process has a narrow fluidisation window: if inlet air temperature exceeds 65°C, the maltodextrin binder vitrifies and forms a hard shell that retards dissolution; if product bed temperature falls below 35°C, the binder solution wets the API powder and produces agglomerates above 2000 µm. These limits require continuous dew-point monitoring of the inlet air, with supply-air moisture below 8 g/kg dry air to avoid caking on the product filter bags.